| pubmed-article:10592433 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10592433 | lifeskim:mentions | umls-concept:C0042133 | lld:lifeskim |
| pubmed-article:10592433 | lifeskim:mentions | umls-concept:C0282402 | lld:lifeskim |
| pubmed-article:10592433 | lifeskim:mentions | umls-concept:C0596290 | lld:lifeskim |
| pubmed-article:10592433 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10592433 | lifeskim:mentions | umls-concept:C1268900 | lld:lifeskim |
| pubmed-article:10592433 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10592433 | pubmed:dateCreated | 2000-1-13 | lld:pubmed |
| pubmed-article:10592433 | pubmed:abstractText | Cell proliferation in uterine leiomyomas treated preoperatively with either nafarelin (400 microg/day) for 3 months (7 patients) or nafarelin plus hormone (oestradiol + norethisterone) add-back therapy (6 patients) was investigated by automatic image analysis of frozen tissue sections using immunohistochemistry with anti-proliferating cell nuclear antigen antibody. GnRHa therapy decreased cell proliferation in leiomyomas to a level corresponding to the situation previously seen in postmenopausal leiomyomas. However, there was no consistent correlation between cell proliferation and shrinkage of leiomyomal size. The hormone add-back therapy moderated the influence of GnRHa on cell proliferation and completely blocked a decrease in size of leiomyomas in our patients. | lld:pubmed |
| pubmed-article:10592433 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10592433 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10592433 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10592433 | pubmed:issn | 0378-7346 | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:TuimalaRR | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:KivinenSS | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:RantalaII | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:TeisalaKK | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:KujansuuEE | lld:pubmed |
| pubmed-article:10592433 | pubmed:author | pubmed-author:RintalaSS | lld:pubmed |
| pubmed-article:10592433 | pubmed:copyrightInfo | Copyright 1999 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:10592433 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10592433 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:10592433 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10592433 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10592433 | pubmed:pagination | 276-9 | lld:pubmed |
| pubmed-article:10592433 | pubmed:dateRevised | 2009-12-16 | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:meshHeading | pubmed-meshheading:10592433... | lld:pubmed |
| pubmed-article:10592433 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10592433 | pubmed:articleTitle | GnRH analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation. | lld:pubmed |
| pubmed-article:10592433 | pubmed:affiliation | Department of Anaesthesiology and Intensive Care, Tampere University Hospital, Tampere, Finland. | lld:pubmed |
| pubmed-article:10592433 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10592433 | pubmed:publicationType | Clinical Trial | lld:pubmed |
